Answers are grounded in this paper and cite their sources.
This cross-sectional descriptive study mapped the AI-enabled medical device landscape in Australia and the United States using the FDA AI/ML-enabled medical device list and the TGA AI-enabled medical devices list, current as of 5th January 2026. We compared medical specialty distribution, AI function, regulatory risk classification, and manufacturer origin, and characterised the overlap between the two lists. We identified 1,357 FDA listings and 125 TGA listings. Radiology dominated both markets (FDA 76.5%, TGA 60.8%), but Australia had different specialty diversity to the US, including orthopaedic (2.4%) and dental (3.2%) devices. AI image and signal interpretation was most common (FDA 57.5%, TGA 38.4%), whereas measurement, treatment planning, and workflow support were relatively more prominent in Australia. Nearly all FDA devices were Class II (98.8%), while TGA devices spanned low to high-risk classes. Top contributors to Australia’s AI market were the USA (28.8%), Australia (9.6%), and China (8.8%). Of the 125 TGA listings, 71 (56.8%) had a matching FDA listing. Among these 71 matched TGA listings, 15 were listed in Australia prior to the USA, while the remaining 56 were FDA-listed first. Australia’s AI device market is smaller, but still diverse, and includes multiple Australian-headquartered manufacturers. The substantial overlap between the two lists, predominantly with prior FDA listing, suggests the Australian market draws on internationally developed technologies, although listing dates do not establish when devices became available to clinicians. These descriptive findings provide a benchmark for future comparative and longitudinal research as both markets continue to develop.
No takes yet. Share an insight, caveat, or question.
Rowe et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: